Asset Details
Do you wish to reserve the book?
Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression?
Do you wish to request the book?
Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression?
2020
Overview
Intraductal papillary mucinous neoplasms (IPMN) are precursors of pancreatic cancer. Potential biomarkers of IPMN progression have not been identified in urine. A few urinary biomarkers were reported to be predictive of pancreatic ductal adenocarcinoma (PDAC). Here, we seek to assess their ability to detect high-risk IPMN.
Urine was collected from patients undergoing pancreatic resection and healthy controls. TIMP-1(Tissue Inhibitor of Metalloproteinase-1), LYVE-1(Lymphatic Vessel Endothelial Receptor 1), and PGEM(Prostaglandin E Metabolite) levels were determined by ELISA and analyzed by Kruskal-Wallis.
Median urinary TIMP-1 levels were significantly lower in healthy controls (n = 9; 0.32 ng/mg creatinine) compared to PDAC (n = 13; 1.95) but not significantly different between low/moderate-grade (n = 20; 0.71) and high-grade/invasive IPMN (n = 20; 1.12). No significant difference in urinary LYVE-1 was detected between IPMN low/moderate (n = 16; 0.37 ng/mg creatinine) and high/invasive grades (n = 21; 0.09). Urinary PGEM levels were not significantly different between groups.
Urinary TIMP-1, LYVE-1, and PGEM do not correlate with malignant potential of pancreatic cysts.
•Urinary TIMP-1 and LYVE-1 can differentiate healthy controls from pancreatic cancer.•Urinary TIMP-1 and LYVE-1 cannot distinguish between low- and high-risk IPMN.•Urinary PGEM does not correlate with malignant potential of pancreatic cysts.
Publisher
Elsevier Inc,Elsevier Limited
Subject
/ Adenocarcinoma, Mucinous - surgery
/ Adenocarcinoma, Mucinous - urine
/ Adult
/ Age
/ Aged
/ Cancer
/ Carcinoma, Pancreatic Ductal - surgery
/ Carcinoma, Pancreatic Ductal - urine
/ Cysts
/ Female
/ Gender
/ Humans
/ Intraductal papillary mucinous neoplasm
/ Male
/ Pancreatic Neoplasms - surgery
/ Pancreatic Neoplasms - urine
/ Patients
/ Tissue inhibitor of metalloproteinase 1
/ Tissue Inhibitor of Metalloproteinase-1 - urine
/ Tumors
/ Urine
